DOI: 10.12890/2026_007447

Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature

Authors

  • Kai Xiong Lim Department of Internal Medicine, Sengkang General Hospital, Singapore
  • Sok Boon Tay Department of Respiratory Medicine, Sengkang General Hospital, Singapore
  • Yi Loong Benny Cheong Department of Internal Medicine, Sengkang General Hospital, Singapore
  • Zongwen Wee Department of Endocrinology, Sengkang General Hospital, Singapore

lim.kai.xiong@singhealth.com.sg

Keywords

Insulinoma, hypoglycaemia, glucagon-like peptide-1 receptor agonist (GLP-1), multiple endocrine neoplasia type 1 (MEN1)

Abstract

Introduction: Insulinoma is a rare neuroendocrine tumour that secretes insulin resulting in hypoglycaemia. The initial diagnosis of insulinoma can be challenging in view of the intermittent and non-specific symptoms. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being prescribed for the treatment of diabetes mellitus and obesity. We discuss a case of how a GLP-1 receptor agonist unmasked a previously undiagnosed insulinoma.
Case description: A 48-year-old woman with class III obesity was started on subcutaneous semaglutide, a GLP-1 receptor agonist, for weight management. After the initiation of semaglutide, she started having recurrent symptoms of hypoglycaemia that was initially unevaluated. The symptoms worsened when the patient developed an episode of gastroenteritis, which resulted in her fainting. Further work up of the hypoglycaemia revealed endogenous hyperinsulinaemia, with imaging confirming the diagnosis of an insulinoma. Insulinoma is known to overexpress GLP-1 receptors that bind to GLP-1 receptor agonists. Coupled with the caloric restriction from GLP-1 receptor agonist, exacerbated by acute gastroenteritis, this resulted in the patient presenting with recurrent symptomatic hypoglycaemia.
Conclusion: GLP-1 receptor agonists can unmask previously asymptomatic insidious insulinomas. Since GLP-1 receptor agonist alone should rarely cause hypoglycaemia, a thorough evaluation is required to determine the underlying cause of this patient’s recurrent hypoglycaemia. This is especially important with the increasing usage of GLP-1 receptor agonists.

View the entire article

Downloads

References

  1. Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the patient: insulinoma. J Clin Endocrinol Metab 2024;109:1109–1118. doi: 10.1210/clinem/dgad641.
  2. Looi E, Lawler HM. Non-diabetic hypoglycemia: evaluation and management in adults. J Clin Med 2025;14:4393. doi: 10.3390/jcm14134393.
  3. Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med 2026;394:1313–1324. doi: 10.1056/NEJMra2500106.
  4. Howarth S, Ho TW, Wimbury J, Casey R. Managing hypoglycaemia in patients with insulinoma—a tertiary centre experience and review of the literature. Clin Endocrinol (Oxf) 2025;102:344–354. doi: 10.1111/cen.15188.
  5. Brandi ML, Pieterman CRC, English KA, Lines KE, Shariq OA, Marini F, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol 2025;13:699–721. doi: 10.1016/S2213-8587(25)00119-6.
  6. Palani G, Stortz E, Moheet A. Clinical presentation and diagnostic approach to hypoglycemia in adults without diabetes mellitus. Endocr Pract 2023;29:286–294. doi: 10.1016/j.eprac.2022.11.010.
  7. Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med 2025;31:951–962. doi: 10.1038/s41591-024-03412-w.
  8. Ruby RJ, Armato JP, Pyke C, Peters AL. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma. Diabetes Care 2014;37:e177–e178. doi: 10.2337/dc14-0514.
  9. Jain AK, Amin T, Chalasani K, Holland SW. A hidden culprit: insulinoma masquerading as GLP-1 agonist-induced hypoglycemia. J Endocr Soc 2025;9(Suppl 1):bvaf149.1081. doi: 10.1210/jendso/bvaf149.1081.
  10. Polisky M, Kamel D, Ku JH. Insulinoma unmasked by tirzepatide: a rare case of postprandial hypoglycemia in a nondiabetic patient. JCEM Case Rep 2026;4:luaf290. doi: 10.1210/jcemcr/luaf290.
  11. Baldera-Rodriguez N, Simo-Campillo N, Sanrregre-Oven P, Lopez EC, Romano R, Goicochea AB. Unmasking an insulinoma: recurrent hypoglycemia in a young patient following GLP-1 receptor agonist therapy—a case report. Oxf Med Case Reports 2026;2026:omaf283. doi: 10.1093/omcr/omaf283.
  12. Simonov E, Berger R, Shishkina O, Sivokha A, Cantrell D. GLP-1 receptor agonist associated unmasking of insulinoma. Eur J Case Rep Intern Med 2026;13:006552. doi: 10.12890/2026_006552.
  13. Danowitz M, De Leon DD. The role of GLP-1 signaling in hypoglycemia due to hyperinsulinism. Front Endocrinol (Lausanne) 2022;13:863184. doi: 10.3389/fendo.2022.863184.
  14. Boss M, Eriksson O, Mikkola K, Eek A, Brom M, Buitinga M, et al. Improved localization of insulinomas using 68Ga-NODAGA-exendin-4 PET/CT. J Nucl Med 2024;65:1959–1964. doi: 10.2967/jnumed.124.268158.

Published

2026-11-19

How to Cite

1.
Lim KX, Tay SB, Cheong YLB, Wee Z. Uncovering an insidious insulinoma with glucagon-like peptide-1 receptor agonist: a case report and review of the literature. EJCRIM [Internet]. 2026 Nov. 19 [cited 2026 Nov. 20];13. Available from: https://ejcrim.com/index.php/ejcrim/article/view/7447

Most read articles by the same author(s)